Jindrich H Kopecek

6982324, Jan 3, 2006

Nov 5, 2002

10/288618

Zheng-Rong Lu - Salt Lake City UT, US
Jindrich Kopecek - Salt Lake City UT, US
Dennis L. Parker - Centerville UT, US

University of Utah Research Foundation - Salt Lake City UT

C07F 5/00

534 15, 424 111, 424 165, 424 936

Novel degradable macromolecular magnetic resonance imaging contrast agents for use in various diagnostic procedures, and methods for synthesizing, using and degrading these agents, are disclosed. The macromolecule contrast agents disclosed in various aspects of this invention are degradable gadolinium compounds which show prolonged plasma retention, and enhanced permeability and retention in solid tumors, but are still capable of being rapidly cleared from the body.

7179487, Feb 20, 2007

Jun 18, 1999

09/336259

Jindrich Kopecek - Salt Lake City UT, US
Russell Stewart - Salt Lake City UT, US
Karin Caldwell - Salt Lake City UT, US
Chung Wang - Salt Lake City UT, US
Chih-Hu Ho - Salt Lake City UT, US

University of Utah Research Foundation - Salt Lake City UT

A61K 9/00
A61K 38/03
A61K 38/16

424484, 424486, 530300, 514 2, 514 42, 514 44

A stimuli-responsive, hybrid hydrogel wherein the bulk of the polymer is made up of relatively inexpensive water soluble polymer strands crosslinked by protein domains. The responsiveness of the gel is controlled or modulated by the protein component. The physical and biological properties of the hydrogel are determined by specifically designed or engineered protein domains. The crosslinking of the protein domains to the water soluble polymers is by means of non-covalent bonding such as chelation or coordination bonding, biotin-avidin bonding, protein—protein interaction and protein-ligand interaction, or by means of covalent bonding. Methods of making and using the polymer-protein hydrogels are disclosed in this application.

7745590, Jun 29, 2010

Aug 15, 2005

11/203799

Zheng-Rong Lu - Salt Lake City UT, US
Jindrich Kopecek - Salt Lake City UT, US
Dennis L. Parker - Centerville UT, US

University of Utah Research Foundation - Salt Lake City UT

C07F 5/00

534 15, 424 111, 424 165, 424 93, 424 934, 424 935, 424 936, 424 9362, 424 9363

Degradable macromolecular magnetic resonance imaging contrast agents for use in various diagnostic procedures, and methods for synthesizing, using and degrading these agents, are described. The macromolecule contrast agents disclosed in various aspects of this invention are degradable gadolinium compounds which show prolonged plasma retention, and enhanced permeability and retention in solid tumors, but are still capable of being rapidly cleared from the body.

20040234497, Nov 25, 2004

Apr 30, 2004

10/476824

Yi Luo - Salt Lake City UT, US
Glenn Prestwich - Salt Lake City UT, US
Jindrich Kopecek - Salt Lake City UT, US
Zheng-Rong Lu - Salt Lake City UT, US

A61K038/19
A61K031/728

424/085100, 514/034000, 514/183000, 514/054000, 514/283000, 514/449000, 530/351000, 536/053000

A cell-targeted polymeric drug delivery system was designed based on the specific interaction between hyaluronic acid (HA) and its cell surface receptors overexpressed on cancer cell surface. The invention relates to compounds composed of a carrier molecule, 5 wherein the carrier molecule contains at least one residue of an anti-cancer agent and at least one residue of a hyaluronic acid. The invention also relates to methods of making and using the compounds thereof.

20050287114, Dec 29, 2005

Jun 10, 2005

11/150865

Dong Wang - Omaha NE, US
Scott Miller - Salt Lake City UT, US
Pavla Kopeckova - Salt Lake City UT, US
Jindrich Kopecek - Salt Lake City UT, US

A61K038/08
A61K031/785
C07C237/26

424078270, 525054100, 525296000, 552205000, 514152000

The present invention provides bone-targeting polymeric drug delivery systems based on HPMA and related copolymers and methods of making thereof. The water-soluble bone-targeting polymeric conjugates of the present invention comprise water-soluble copolymer backbones (P) which are linked, via a first spacer (S), with a bone-related therapeutic agents or drug (D) and, via a second spacer (S), with a bone-targeting moiety (T).

20070287680, Dec 13, 2007

May 5, 2005

11/547872

Vaikunth Cuchelkar - Salt Lake City UT, US
Pavla Kopeckova - Salt Lake City UT, US
C. Peterson - Bountiful UT, US
Jindrich Kopecek - Salt Lake City UT, US

University of Utah Research Foundation - Salt Lake City UT

C12N 15/01
A61K 31/7088
A61K 47/16
A61K 47/28
A61P 35/00

514044000, 435455000, 514772000, 514773000, 514789000

Disclosed is a conjugate comprising a biologically active agent (drug) linked to a subcellular targeting moiety that targets a drug specifically to the nucleus. Targeting is achieved by attaching a steroid hormone (or an analog) to the drug. The steroid hormone attached to the drug binds its corresponding receptor, the formation of the receptor-ligand complex results in the internalization of the complex into the nucleus, thus resulting in nuclear translocation of the drug. Also disclosed is a conjugate (comprising the complex of the drug and the steroid hormone) bound to a polymer by spacers allowing for concurrent passive targeting to the tumor cell (afforded by attachment to the polymer by the EPR effect) and nuclear targeting of the conjugate (due to the presence of the steroid). Using a suitable degradable spacer allows for the release of free drug in the tumor and enhances nuclear targeting efficacy. The polymer can be further linked to a cellular targeting molecule, where the targeting molecule directs the polymer to specific cells. One may thus be able to effectively target drugs to the nucleus of tumor cells. With little or modifications, several therapeutic agents can be targeted using the invention.

20080159959, Jul 3, 2008

Mar 30, 2005

10/591258

Dong Wang - Omaha NE, US
Jindrich Kopecek - Salt Lake City UT, US
Scott C. Miller - Salt Lake City UT, US
Pavla Kopeckova - Salt Lake City UT, US

University of Utah Research Foundation - Salt Lake City UT

A61K 47/48
A61K 47/30
A61K 38/02
A61K 31/44
A61K 38/13
A61K 33/34
A61K 49/12
A61P 29/00
A61K 49/00
A61K 33/24
A61K 31/197
A61K 31/519
A61K 47/38

424 93, 5147723, 514781, 514778, 514774, 514169, 514 2, 514249, 514352, 514562, 514 9, 424649, 424630, 424 91, 424 94

This invention relates to biotechnology, more particularly, to water-soluble polymeric delivery systems for the imaging, evaluation and/or treatment of rheumatoid arthritis and other inflammatory diseases. Using modern MR imaging techniques, the specific accumulation of macromolecules in arthritic joints in adjuvant-induced arthritis in rats is demonstrated. The strong correlation between the uptake and retention of the MR contrast agent labeled polymer with histopathological features of inflammation and local tissue damage demonstrates the practical applications of the macromolecular delivery system of the invention.

20090104143, Apr 23, 2009

Nov 3, 2008

12/290879

Yi Luo - Salt Lake City UT, US
Glenn D. Prestwich - Salt Lake City UT, US
Jindrich Kopecek - Salt Lake City UT, US
Zheng-Rong Lu - Salt Lake City UT, US

University of Utah Research Foundation - Salt Lake City UT

A61K 47/48
A61P 35/00

424 7817

A cell-targeted polymeric drug delivery system was designed based on the specific interaction between hyaluronic acid (HA) and its cell surface receptors overexpressed on cancer cell surface. The invention relates to compounds composed of a carrier molecule, wherein the carrier molecule contains at least one residue of an anti-cancer agent and at least one residue of a hyaluronic acid. The invention also relates to methods of making and using the compounds thereof.